Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acrivon Therapeutics, Inc. (ACRV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Acrivon is a clinical stage biopharmaceutical company focused on precision oncology medicines developed using its Generative Phosphoproteomics AP3 platform, and its filings offer additional context on financial results, clinical programs, and business updates.
Among the documents available for ACRV are current reports on Form 8-K, which Acrivon uses to furnish press releases announcing quarterly financial results and to provide Regulation FD disclosures. For example, the company has filed 8-K reports to attach earnings press releases summarizing research and development expenses, cash and investment balances, and narrative business highlights, as well as to furnish a corporate presentation describing AP3 capabilities, synergy data for ACR-368 and ACR-2316 with immune checkpoint inhibitors, and updates to its pipeline overview.
Through this page, users can track how Acrivon reports its progress with lead programs such as ACR-368, a CHK1/CHK2 inhibitor in a registrational-intent Phase 2 or Phase 2b trial in endometrial cancer, and ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1 development, along with AP3-driven preclinical initiatives. Real-time updates from EDGAR ensure that new ACRV filings, including additional 8-Ks and other periodic reports, are reflected as they become available.
Stock Titan’s interface is designed to pair these filings with AI-powered summaries that explain the key points of each document in clear language. Users can quickly see what each ACRV filing covers—such as financial condition, clinical data highlights, or platform developments—while retaining the ability to open the full SEC text for detailed review, including any exhibits like press releases or corporate presentations incorporated by reference.
Acrivon Therapeutics reported stock option awards to senior executives. The filing shows grants covering 417,210 options and 185,495 options, with exercise rights structured as long-term incentives rather than cash purchases. Twenty-five percent of each grant vests on March 1, 2027, and the remaining options vest in 36 equal monthly installments, conditioned on continued service. Footnotes explain that President and CEO Dr. Peter Blume-Jensen and EVP Dr. Kristina Masson each hold options and disclaim beneficial ownership of their spouse’s securities except for any economic interest.
Acrivon Therapeutics, Inc. is shifting its ACR-368 OncoSignature diagnostic testing fully in-house after completing and certifying an internally owned Clinical Laboratory Improvement Amendment (CLIA) laboratory in Watertown, Massachusetts. This new lab is intended to support development of the company’s current and future targeted therapies.
On February 25, 2026, Acrivon and Akoya Biosciences, a wholly owned subsidiary of Quanterix Corporation, entered into a Termination and Transition Agreement to mutually end their June 17, 2022 OncoSignature Companion Diagnostic Agreement. The termination involves no financial payments between the parties. Quanterix and Acrivon agreed on a transition plan so procedures, materials and know-how from Akoya’s prior ACR-368 OncoSignature work are transferred to Acrivon, while Quanterix continues clinical testing during the changeover to support Acrivon’s registrational-intent Phase 2b study. Effective immediately, Acrivon holds full development and commercialization rights to its proprietary ACR-368 OncoSignature test.
Acrivon Therapeutics described interim Phase 2b data for its CHK1/2 inhibitor ACR-368 in endometrial cancer during a company-sponsored key opinion leader panel held at the ESGO Congress. The trial uses the ACR-368 OncoSignature biomarker to prospectively select patients predicted to benefit.
In the biomarker-positive Arm 1, ACR-368 monotherapy showed an objective response rate of 39% (95% CI, 24–56) in 31 treated subjects, with disease control rate of 80.6% and 16‑week clinical benefit rate of 61.3%. Across arms, better response rates were observed in patients with ≤2 prior lines of therapy, including serous and non‑serous histologies.
Safety data showed mainly hematologic adverse events such as thrombocytopenia, anemia, leukopenia and neutropenia, with no fatal treatment-related events and a notable absence of common non‑hematologic toxicities. The study is expanding to additional U.S. and European sites, with enrollment completion for the serous all‑comer cohort targeted in Q4 2026.
Acrivon Therapeutics reported an insider tax-related share disposition involving its President and CEO, Dr. Peter Blume-Jensen. The company withheld 14,265 shares of common stock at $1.53 per share to cover mandatory taxes due on vested restricted stock units, rather than an open-market sale. After this withholding, Dr. Blume-Jensen directly holds 2,080,204 common shares. The filing also notes 314,127 common shares held indirectly in spousal accounts shared between Dr. Blume-Jensen and co-founder and EVP Dr. Kristina Masson, with each spouse disclaiming beneficial ownership beyond their economic interest.
Acrivon Therapeutics, Inc. Chief Accounting Officer Katharine Peterson reported a small tax-related share disposition. On the vesting of restricted stock units, 116 shares of common stock were withheld by the company to satisfy mandatory tax withholding, valued at $1.63 per share. After this withholding, Peterson directly holds 4,006 shares of Acrivon common stock.
Acrivon Therapeutics, Inc. Chief Legal Officer Mary Miller reported a routine share disposition related to taxes. On the transaction date, 217 shares of common stock were withheld by the company at a price of $1.63 per share to satisfy mandatory tax withholding upon vesting of restricted stock units. After this tax-withholding disposition, she held 33,679 shares of common stock directly.
Acrivon Therapeutics, Inc. Chief Development Officer Erick Gamelin reported a tax-related share disposition. On February 14, 2026, the issuer withheld 471 shares of common stock at $1.63 per share to satisfy mandatory tax withholding upon vesting of restricted stock units. This reduced Gamelin’s directly held common stock to 14,812 shares. The transaction is classified as a disposition for tax withholding, not an open-market purchase or sale.
Acrivon Therapeutics Chief Operating Officer Eric Devroe reported a small tax-related share disposition. On the vesting of restricted stock units, 723 shares of common stock were withheld by the company at a price of $1.63 per share to cover mandatory tax withholding. After this non-market transaction, Devroe directly holds 74,585 shares of Acrivon Therapeutics common stock.
Acrivon Therapeutics insiders reported tax-related share dispositions tied to restricted stock unit vesting. The filing shows 1,302 shares of Common Stock disposed at $1.63 per share, leaving 2,094,469 shares owned following this transaction.
A separate indirect transaction reports a tax-withholding disposition of 579 Common Stock shares at $1.63 per share, with 314,127 shares owned indirectly afterward. Footnotes explain shares were withheld by the issuer to satisfy mandatory tax withholding and that certain holdings are through a spouse, with each spouse disclaiming beneficial ownership beyond their pecuniary interest.
Acrivon Therapeutics, Inc. insider Mary Miller, the company’s Chief Legal Officer, reported a routine share withholding related to equity compensation. On 01/17/2026, 659 shares of common stock were withheld at a price of $1.98 per share to cover mandatory tax withholding when her restricted stock units vested. After this transaction, she beneficially owned 33,896 shares of Acrivon common stock, held directly. This type of transaction does not represent an open-market sale but an automatic tax-related adjustment.